Filing Details

Accession Number:
0001209191-22-052799
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-10-05 17:00:21
Reporting Period:
2022-10-03
Accepted Time:
2022-10-05 17:00:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1840574 Verve Therapeutics Inc. VERV Pharmaceutical Preparations (2834) 824800132
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1864112 Sekar Kathiresan C/O Verve Therapeutics
500 Technology Square, Suite 901
Cambridge MA 02139
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-10-03 50,000 $1.39 367,839 No 4 M Direct
Common Stock Disposition 2022-10-03 28,911 $33.02 338,928 No 4 S Direct
Common Stock Disposition 2022-10-03 11,185 $34.13 327,743 No 4 S Direct
Common Stock Disposition 2022-10-03 9,904 $34.97 317,839 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2022-10-03 50,000 $0.00 50,000 $1.39
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
138,995 2029-04-14 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 240,997 Indirect Kathiresan Family 2021 Irrevocable Trust
Common Stock 80,997 Indirect Sekar Kathiresan 2021 Irrevocable Trust
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.59 to $33.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), and (4) of this Form 4.
  3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.59 to $34.59, inclusive.
  4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.61 to $35.50, inclusive.
  5. The remaining shares underlying this option, which was granted on April 15, 2019, vest in equal monthly installments until March 25, 2024.